This article is more than 5 years old. Information may no longer be current.

Australia grants patent for Dropless Therapy formulations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Australian Patent Office has issued Imprimis Pharmaceuticals its first patent covering Dropless Therapy formulations, the company announced in a press release.

The patent covers “pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an anti-inflammatory agent,” the release said, and it will expire March 27, 2034.

“This composition patent granted by the Australian Patent Office covering our flagship Dropless Therapy program is an important milestone and validation for our company, particularly in light of our ability to ship Dropless Therapy formulations overseas from our FDA-registered outsourcing facility,” Mark L. Baum, Imprimis CEO, said in the release. “We anticipate this will be the first of several patents to be issued for our Dropless Therapy, LessDrops and other key ophthalmic products in the U.S. and abroad. Protecting these valuable assets is critical, and the issuance of this key patent not only strengthens our IP portfolio, but sets a strong precedent that our core technology is truly novel and innovative.”